[
    {
        "id": 8418,
        "drug_name": "DUPIXENT (dupilumab) - (PRIME)",
        "clinical_trial_id": "NCT04183335",
        "has_trial_insight_page": 0,
        "indication": "Prurigo nodularis (PN)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-09-28",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/SNY\/news\/95249",
        "note": "Approved September 28, 2022.",
        "company_entity_id": 388,
        "company_ticker": "REGN",
        "company_name": "Regeneron Pharmaceuticals Inc.",
        "company_price": "970.5700",
        "company_change": 6.13,
        "company_percent_change": 0.64,
        "company_optionable": 1,
        "company_number_of_shares": 109761896,
        "price_change_sparkline": [
            [
                942.78,
                1706677200
            ],
            [
                957.78,
                1706763600
            ],
            [
                945.18,
                1706850000
            ],
            [
                936.33,
                1707109200
            ],
            [
                937.81,
                1707195600
            ],
            [
                938.49,
                1707282000
            ],
            [
                946.43,
                1707368400
            ],
            [
                953.42,
                1707454800
            ],
            [
                947.06,
                1707714000
            ],
            [
                940.48,
                1707800400
            ],
            [
                947.82,
                1707886800
            ],
            [
                954.73,
                1707973200
            ],
            [
                948.05,
                1708059600
            ],
            [
                946.87,
                1708405200
            ],
            [
                952.84,
                1708491600
            ],
            [
                964.89,
                1708578000
            ],
            [
                981.2,
                1708664400
            ],
            [
                989.28,
                1708923600
            ],
            [
                993.35,
                1709010000
            ],
            [
                987.61,
                1709096400
            ],
            [
                966.09,
                1709182800
            ],
            [
                982.82,
                1709269200
            ],
            [
                971.19,
                1709528400
            ],
            [
                965.21,
                1709614800
            ],
            [
                972.1,
                1709701200
            ],
            [
                973.31,
                1709787600
            ],
            [
                968.83,
                1709874000
            ],
            [
                964.44,
                1710129600
            ],
            [
                970.57,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8418,
        "drug_name": "DUPIXENT (dupilumab) - (PRIME)",
        "clinical_trial_id": "NCT04183335",
        "has_trial_insight_page": 0,
        "indication": "Prurigo nodularis (PN)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-09-28",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/SNY\/news\/95249",
        "note": "Approved September 28, 2022.",
        "company_entity_id": 389,
        "company_ticker": "SNY",
        "company_name": "Sanofi",
        "company_price": "48.4600",
        "company_change": 0.11,
        "company_percent_change": 0.23,
        "company_optionable": 1,
        "company_number_of_shares": 2529599938,
        "price_change_sparkline": [
            [
                49.9,
                1706677200
            ],
            [
                48.41,
                1706763600
            ],
            [
                47.23,
                1706850000
            ],
            [
                46.95,
                1707109200
            ],
            [
                47.06,
                1707195600
            ],
            [
                46.92,
                1707282000
            ],
            [
                46.56,
                1707368400
            ],
            [
                46.5,
                1707454800
            ],
            [
                46.34,
                1707714000
            ],
            [
                45.75,
                1707800400
            ],
            [
                45.8,
                1707886800
            ],
            [
                46.39,
                1707973200
            ],
            [
                46.18,
                1708059600
            ],
            [
                46.85,
                1708405200
            ],
            [
                47.92,
                1708491600
            ],
            [
                47.8,
                1708578000
            ],
            [
                48.77,
                1708664400
            ],
            [
                48.2,
                1708923600
            ],
            [
                48.21,
                1709010000
            ],
            [
                48,
                1709096400
            ],
            [
                47.85,
                1709182800
            ],
            [
                47.29,
                1709269200
            ],
            [
                47.15,
                1709528400
            ],
            [
                47.5,
                1709614800
            ],
            [
                47.68,
                1709701200
            ],
            [
                48.06,
                1709787600
            ],
            [
                48.25,
                1709874000
            ],
            [
                48.35,
                1710129600
            ],
            [
                48.46,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9669,
        "drug_name": "FIRDAPSE",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Pediatric Lambert-Eaton myasthenic syndrome (LEMS)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-09-29",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/CPRX\/news\/95365",
        "note": "sNDA approved September 29, 2022.",
        "company_entity_id": 100,
        "company_ticker": "CPRX",
        "company_name": "Catalyst Pharmaceuticals Inc.",
        "company_price": "16.2000",
        "company_change": 0.1,
        "company_percent_change": 0.62,
        "company_optionable": 1,
        "company_number_of_shares": 117863258,
        "price_change_sparkline": [
            [
                14.4,
                1706677200
            ],
            [
                14.43,
                1706763600
            ],
            [
                13.62,
                1706850000
            ],
            [
                13.39,
                1707109200
            ],
            [
                13.75,
                1707195600
            ],
            [
                13.35,
                1707282000
            ],
            [
                13.37,
                1707368400
            ],
            [
                13.64,
                1707454800
            ],
            [
                13.64,
                1707714000
            ],
            [
                13.18,
                1707800400
            ],
            [
                13.48,
                1707886800
            ],
            [
                13.89,
                1707973200
            ],
            [
                14,
                1708059600
            ],
            [
                13.79,
                1708405200
            ],
            [
                13.71,
                1708491600
            ],
            [
                13.9,
                1708578000
            ],
            [
                14.04,
                1708664400
            ],
            [
                14.18,
                1708923600
            ],
            [
                14.35,
                1709010000
            ],
            [
                14.56,
                1709096400
            ],
            [
                16.03,
                1709182800
            ],
            [
                17.01,
                1709269200
            ],
            [
                16.69,
                1709528400
            ],
            [
                16.27,
                1709614800
            ],
            [
                15.86,
                1709701200
            ],
            [
                16.64,
                1709787600
            ],
            [
                16.25,
                1709874000
            ],
            [
                16.1,
                1710129600
            ],
            [
                16.2,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8798,
        "drug_name": "RELYVRIO (sodium phenylbutyrate and taurursodiol)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Amyotrophic lateral sclerosis (ALS)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-09-29",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/AMLX\/news\/95406",
        "note": "Approved September 29, 2022.",
        "company_entity_id": 1071,
        "company_ticker": "AMLX",
        "company_name": "Amylyx Pharmaceuticals Inc.",
        "company_price": "3.4400",
        "company_change": -0.36,
        "company_percent_change": -9.47,
        "company_optionable": 1,
        "company_number_of_shares": 67782139,
        "price_change_sparkline": [
            [
                16,
                1706677200
            ],
            [
                16.57,
                1706763600
            ],
            [
                15.78,
                1706850000
            ],
            [
                15.3,
                1707109200
            ],
            [
                15.56,
                1707195600
            ],
            [
                15.12,
                1707282000
            ],
            [
                15.46,
                1707368400
            ],
            [
                16.14,
                1707454800
            ],
            [
                16.25,
                1707714000
            ],
            [
                14.96,
                1707800400
            ],
            [
                15.07,
                1707886800
            ],
            [
                15.38,
                1707973200
            ],
            [
                15.88,
                1708059600
            ],
            [
                14.91,
                1708405200
            ],
            [
                15.31,
                1708491600
            ],
            [
                18.54,
                1708578000
            ],
            [
                17.65,
                1708664400
            ],
            [
                17.56,
                1708923600
            ],
            [
                19,
                1709010000
            ],
            [
                19.57,
                1709096400
            ],
            [
                18.85,
                1709182800
            ],
            [
                18.71,
                1709269200
            ],
            [
                19.14,
                1709528400
            ],
            [
                18.85,
                1709614800
            ],
            [
                19.05,
                1709701200
            ],
            [
                18.97,
                1709787600
            ],
            [
                3.36,
                1709874000
            ],
            [
                3.8,
                1710129600
            ],
            [
                3.44,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9857,
        "drug_name": "Menveo (Meningococcal Oligosaccharide Diptheria CRM197 Conjugate Vaccine)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Meningococcal disease",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-10-17",
        "link": "https:\/\/otp.tools.investis.com\/generic\/regulatory-story.aspx?cid=410&newsid=1636304",
        "note": "Approved October 17, 2022.",
        "company_entity_id": 379,
        "company_ticker": "GSK",
        "company_name": "GSK plc American Depositary Shares (Each representing two)",
        "company_price": "43.2700",
        "company_change": 0.35,
        "company_percent_change": 0.82,
        "company_optionable": 1,
        "company_number_of_shares": 2058516719,
        "price_change_sparkline": [
            [
                39.0637603938206,
                1706677200
            ],
            [
                40.2424083367376,
                1706763600
            ],
            [
                40.3315497777986,
                1706850000
            ],
            [
                41.1734411655964,
                1707109200
            ],
            [
                41.3517240477183,
                1707195600
            ],
            [
                41.6191483709012,
                1707282000
            ],
            [
                41.4210562796546,
                1707368400
            ],
            [
                41.5101977207156,
                1707454800
            ],
            [
                40.67821093748,
                1707714000
            ],
            [
                40.9951582834745,
                1707800400
            ],
            [
                41.40124707053,
                1707886800
            ],
            [
                41.371533256843,
                1707973200
            ],
            [
                41.5399115344025,
                1708059600
            ],
            [
                41.6191483709012,
                1708405200
            ],
            [
                41.5399115344025,
                1708491600
            ],
            [
                42.16,
                1708578000
            ],
            [
                42.22,
                1708664400
            ],
            [
                42.34,
                1708923600
            ],
            [
                42.38,
                1709010000
            ],
            [
                42.34,
                1709096400
            ],
            [
                41.9,
                1709182800
            ],
            [
                42.03,
                1709269200
            ],
            [
                42.44,
                1709528400
            ],
            [
                42.6,
                1709614800
            ],
            [
                42.62,
                1709701200
            ],
            [
                43.58,
                1709787600
            ],
            [
                43.14,
                1709874000
            ],
            [
                42.92,
                1710129600
            ],
            [
                43.27,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8354,
        "drug_name": "RINVOQ (upadacitinib) - (SELECT-AXIS 2)",
        "clinical_trial_id": "NCT04169373",
        "has_trial_insight_page": 0,
        "indication": "Non-radiographic axial spondyloarthritis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-10-21",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/ABBV\/news\/97722",
        "note": "FDA. Approved on October 21, 2022.",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6155,
        "drug_name": "IMFINZI (Durvalumab) + tremelimumab  - (HIMALAYA)",
        "clinical_trial_id": "NCT03298451",
        "has_trial_insight_page": 1,
        "indication": "Hepatocellular carcinoma (HCC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-10-24",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/AZN\/news\/97816",
        "note": "Approved October 24, 2022.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6721,
        "drug_name": "DUPIXENT (dupilumab) - (PRIME2)",
        "clinical_trial_id": "NCT04202679",
        "has_trial_insight_page": 0,
        "indication": "Prurigo nodularis (PN)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-10-27",
        "link": "https:\/\/www.sanofi.com\/dam\/jcr:755cd6a6-27de-473a-bfa6-e5332c0caab2\/2022_10_28_Sanofi_Q3_Results_2022.pdf",
        "note": "Approved in 3Q 2022.",
        "company_entity_id": 388,
        "company_ticker": "REGN",
        "company_name": "Regeneron Pharmaceuticals Inc.",
        "company_price": "970.5700",
        "company_change": 6.13,
        "company_percent_change": 0.64,
        "company_optionable": 1,
        "company_number_of_shares": 109761896,
        "price_change_sparkline": [
            [
                942.78,
                1706677200
            ],
            [
                957.78,
                1706763600
            ],
            [
                945.18,
                1706850000
            ],
            [
                936.33,
                1707109200
            ],
            [
                937.81,
                1707195600
            ],
            [
                938.49,
                1707282000
            ],
            [
                946.43,
                1707368400
            ],
            [
                953.42,
                1707454800
            ],
            [
                947.06,
                1707714000
            ],
            [
                940.48,
                1707800400
            ],
            [
                947.82,
                1707886800
            ],
            [
                954.73,
                1707973200
            ],
            [
                948.05,
                1708059600
            ],
            [
                946.87,
                1708405200
            ],
            [
                952.84,
                1708491600
            ],
            [
                964.89,
                1708578000
            ],
            [
                981.2,
                1708664400
            ],
            [
                989.28,
                1708923600
            ],
            [
                993.35,
                1709010000
            ],
            [
                987.61,
                1709096400
            ],
            [
                966.09,
                1709182800
            ],
            [
                982.82,
                1709269200
            ],
            [
                971.19,
                1709528400
            ],
            [
                965.21,
                1709614800
            ],
            [
                972.1,
                1709701200
            ],
            [
                973.31,
                1709787600
            ],
            [
                968.83,
                1709874000
            ],
            [
                964.44,
                1710129600
            ],
            [
                970.57,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6721,
        "drug_name": "DUPIXENT (dupilumab) - (PRIME2)",
        "clinical_trial_id": "NCT04202679",
        "has_trial_insight_page": 0,
        "indication": "Prurigo nodularis (PN)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-10-27",
        "link": "https:\/\/www.sanofi.com\/dam\/jcr:755cd6a6-27de-473a-bfa6-e5332c0caab2\/2022_10_28_Sanofi_Q3_Results_2022.pdf",
        "note": "Approved in 3Q 2022.",
        "company_entity_id": 389,
        "company_ticker": "SNY",
        "company_name": "Sanofi",
        "company_price": "48.4600",
        "company_change": 0.11,
        "company_percent_change": 0.23,
        "company_optionable": 1,
        "company_number_of_shares": 2529599938,
        "price_change_sparkline": [
            [
                49.9,
                1706677200
            ],
            [
                48.41,
                1706763600
            ],
            [
                47.23,
                1706850000
            ],
            [
                46.95,
                1707109200
            ],
            [
                47.06,
                1707195600
            ],
            [
                46.92,
                1707282000
            ],
            [
                46.56,
                1707368400
            ],
            [
                46.5,
                1707454800
            ],
            [
                46.34,
                1707714000
            ],
            [
                45.75,
                1707800400
            ],
            [
                45.8,
                1707886800
            ],
            [
                46.39,
                1707973200
            ],
            [
                46.18,
                1708059600
            ],
            [
                46.85,
                1708405200
            ],
            [
                47.92,
                1708491600
            ],
            [
                47.8,
                1708578000
            ],
            [
                48.77,
                1708664400
            ],
            [
                48.2,
                1708923600
            ],
            [
                48.21,
                1709010000
            ],
            [
                48,
                1709096400
            ],
            [
                47.85,
                1709182800
            ],
            [
                47.29,
                1709269200
            ],
            [
                47.15,
                1709528400
            ],
            [
                47.5,
                1709614800
            ],
            [
                47.68,
                1709701200
            ],
            [
                48.06,
                1709787600
            ],
            [
                48.25,
                1709874000
            ],
            [
                48.35,
                1710129600
            ],
            [
                48.46,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9901,
        "drug_name": "Vemlidy (tenofovir alafenamide)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Hepatitis B virus (HBV) infection in pediatric patients 12 years of age and older",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-11-02",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/GILD\/news\/99035",
        "note": "Approved November 2, 2022.",
        "company_entity_id": 378,
        "company_ticker": "GILD",
        "company_name": "Gilead Sciences Inc.",
        "company_price": "75.0800",
        "company_change": -0.24,
        "company_percent_change": -0.31999999999999995,
        "company_optionable": 1,
        "company_number_of_shares": 1245774616,
        "price_change_sparkline": [
            [
                78.26,
                1706677200
            ],
            [
                78.16,
                1706763600
            ],
            [
                76.96,
                1706850000
            ],
            [
                76.71,
                1707109200
            ],
            [
                77.72,
                1707195600
            ],
            [
                74.42,
                1707282000
            ],
            [
                73.8,
                1707368400
            ],
            [
                73.67,
                1707454800
            ],
            [
                74.45,
                1707714000
            ],
            [
                73.53,
                1707800400
            ],
            [
                73.04,
                1707886800
            ],
            [
                73.37,
                1707973200
            ],
            [
                71.58,
                1708059600
            ],
            [
                72.04,
                1708405200
            ],
            [
                73.2,
                1708491600
            ],
            [
                72.78,
                1708578000
            ],
            [
                73.55,
                1708664400
            ],
            [
                72.95,
                1708923600
            ],
            [
                73.02,
                1709010000
            ],
            [
                72.7,
                1709096400
            ],
            [
                72.1,
                1709182800
            ],
            [
                72.31,
                1709269200
            ],
            [
                72.25,
                1709528400
            ],
            [
                72.99,
                1709614800
            ],
            [
                72.63,
                1709701200
            ],
            [
                73.66,
                1709787600
            ],
            [
                75.12,
                1709874000
            ],
            [
                75.32,
                1710129600
            ],
            [
                75.08,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9903,
        "drug_name": "Leuprolide Acetate Injection",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Advanced prostatic cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-11-02",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/AMRX\/news\/99060",
        "note": "FDA Abbreviated New Drug Application (ANDA) approval on November 2, 2022.",
        "company_entity_id": 543,
        "company_ticker": "AMRX",
        "company_name": "Amneal Pharmaceuticals Inc.",
        "company_price": "5.3100",
        "company_change": -0.06999999999999995,
        "company_percent_change": -1.3,
        "company_optionable": 1,
        "company_number_of_shares": 306544199,
        "price_change_sparkline": [
            [
                5.35,
                1706677200
            ],
            [
                5.51,
                1706763600
            ],
            [
                5.52,
                1706850000
            ],
            [
                5.52,
                1707109200
            ],
            [
                5.6,
                1707195600
            ],
            [
                5.36,
                1707282000
            ],
            [
                5.46,
                1707368400
            ],
            [
                5.57,
                1707454800
            ],
            [
                5.85,
                1707714000
            ],
            [
                5.6,
                1707800400
            ],
            [
                5.82,
                1707886800
            ],
            [
                5.89,
                1707973200
            ],
            [
                5.9,
                1708059600
            ],
            [
                5.78,
                1708405200
            ],
            [
                5.73,
                1708491600
            ],
            [
                5.69,
                1708578000
            ],
            [
                5.8,
                1708664400
            ],
            [
                5.82,
                1708923600
            ],
            [
                5.71,
                1709010000
            ],
            [
                5.52,
                1709096400
            ],
            [
                5.52,
                1709182800
            ],
            [
                5.47,
                1709269200
            ],
            [
                5.4,
                1709528400
            ],
            [
                5.34,
                1709614800
            ],
            [
                5.31,
                1709701200
            ],
            [
                5.31,
                1709787600
            ],
            [
                5.39,
                1709874000
            ],
            [
                5.38,
                1710129600
            ],
            [
                5.31,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9947,
        "drug_name": "ADCETRIS (brentuximab vedotin)",
        "clinical_trial_id": "NCT02166463",
        "has_trial_insight_page": 0,
        "indication": "Previously untreated high risk classical Hodgkin lymphoma (cHL)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-11-10",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/SGEN\/news\/100744",
        "note": "Approved November 10, 2022.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4485,
        "drug_name": "IMFINZI (Durvalumab) + tremelimumab",
        "clinical_trial_id": "NCT03164616",
        "has_trial_insight_page": 1,
        "indication": "Non-small cell lung cancer (NSCLC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-11-11",
        "link": "https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/imfinzi-and-imjudo-approved-in-us-for-lung-cancer.html",
        "note": "Approved November 11, 2022.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9964,
        "drug_name": "ELAHERE (mirvetuximab soravtansine-gynx)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Platinum-Resistant Ovarian Cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-11-14",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/IMGN\/news\/101248",
        "note": "Approved November 14, 2022.",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5169,
        "drug_name": "TZIELD (teplizumab-mzwv)",
        "clinical_trial_id": "NCT03875729",
        "has_trial_insight_page": 1,
        "indication": "Type 1 diabetes",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-11-17",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/PRVB\/news\/101694",
        "note": "Approved November 17, 2022.",
        "company_entity_id": 389,
        "company_ticker": "SNY",
        "company_name": "Sanofi",
        "company_price": "48.4600",
        "company_change": 0.11,
        "company_percent_change": 0.23,
        "company_optionable": 1,
        "company_number_of_shares": 2529599938,
        "price_change_sparkline": [
            [
                49.9,
                1706677200
            ],
            [
                48.41,
                1706763600
            ],
            [
                47.23,
                1706850000
            ],
            [
                46.95,
                1707109200
            ],
            [
                47.06,
                1707195600
            ],
            [
                46.92,
                1707282000
            ],
            [
                46.56,
                1707368400
            ],
            [
                46.5,
                1707454800
            ],
            [
                46.34,
                1707714000
            ],
            [
                45.75,
                1707800400
            ],
            [
                45.8,
                1707886800
            ],
            [
                46.39,
                1707973200
            ],
            [
                46.18,
                1708059600
            ],
            [
                46.85,
                1708405200
            ],
            [
                47.92,
                1708491600
            ],
            [
                47.8,
                1708578000
            ],
            [
                48.77,
                1708664400
            ],
            [
                48.2,
                1708923600
            ],
            [
                48.21,
                1709010000
            ],
            [
                48,
                1709096400
            ],
            [
                47.85,
                1709182800
            ],
            [
                47.29,
                1709269200
            ],
            [
                47.15,
                1709528400
            ],
            [
                47.5,
                1709614800
            ],
            [
                47.68,
                1709701200
            ],
            [
                48.06,
                1709787600
            ],
            [
                48.25,
                1709874000
            ],
            [
                48.35,
                1710129600
            ],
            [
                48.46,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9975,
        "drug_name": "Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) - (Monday\/Wednesday\/Friday dosing)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-11-18",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/JAZZ\/news\/101766",
        "note": "Approved November 18, 2022.",
        "company_entity_id": 381,
        "company_ticker": "JAZZ",
        "company_name": "Jazz Pharmaceuticals plc",
        "company_price": "115.7900",
        "company_change": -0.84,
        "company_percent_change": -0.72,
        "company_optionable": 1,
        "company_number_of_shares": 62345283,
        "price_change_sparkline": [
            [
                122.72,
                1706677200
            ],
            [
                123.68,
                1706763600
            ],
            [
                122.9,
                1706850000
            ],
            [
                121.98,
                1707109200
            ],
            [
                124.71,
                1707195600
            ],
            [
                122.94,
                1707282000
            ],
            [
                122.67,
                1707368400
            ],
            [
                123.43,
                1707454800
            ],
            [
                124.24,
                1707714000
            ],
            [
                121.83,
                1707800400
            ],
            [
                122.24,
                1707886800
            ],
            [
                126.82,
                1707973200
            ],
            [
                126.78,
                1708059600
            ],
            [
                126.36,
                1708405200
            ],
            [
                128.42,
                1708491600
            ],
            [
                128.45,
                1708578000
            ],
            [
                132.28,
                1708664400
            ],
            [
                132.77,
                1708923600
            ],
            [
                132.26,
                1709010000
            ],
            [
                129.7,
                1709096400
            ],
            [
                118.9,
                1709182800
            ],
            [
                118.85,
                1709269200
            ],
            [
                117.53,
                1709528400
            ],
            [
                118.42,
                1709614800
            ],
            [
                117.19,
                1709701200
            ],
            [
                116.37,
                1709787600
            ],
            [
                117.53,
                1709874000
            ],
            [
                116.63,
                1710129600
            ],
            [
                115.79,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2324,
        "drug_name": "HEMGENIX (Etranacogene dezaparvovec)",
        "clinical_trial_id": "NCT03569891",
        "has_trial_insight_page": 0,
        "indication": "Hemophilia B",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-11-22",
        "link": "https:\/\/www.uniqure.com\/investors-media\/press-releases",
        "note": "Approved November 22, 2022.",
        "company_entity_id": 257,
        "company_ticker": "QURE",
        "company_name": "uniQure N.V.",
        "company_price": "5.1500",
        "company_change": 0.01,
        "company_percent_change": 0.19,
        "company_optionable": 1,
        "company_number_of_shares": 47838275,
        "price_change_sparkline": [
            [
                5.56,
                1706677200
            ],
            [
                5.56,
                1706763600
            ],
            [
                5.39,
                1706850000
            ],
            [
                5.42,
                1707109200
            ],
            [
                5.96,
                1707195600
            ],
            [
                5.61,
                1707282000
            ],
            [
                5.47,
                1707368400
            ],
            [
                5.93,
                1707454800
            ],
            [
                5.95,
                1707714000
            ],
            [
                5.32,
                1707800400
            ],
            [
                5.29,
                1707886800
            ],
            [
                5.48,
                1707973200
            ],
            [
                5.85,
                1708059600
            ],
            [
                6.25,
                1708405200
            ],
            [
                6.26,
                1708491600
            ],
            [
                6.28,
                1708578000
            ],
            [
                6.32,
                1708664400
            ],
            [
                6.38,
                1708923600
            ],
            [
                6.75,
                1709010000
            ],
            [
                6.69,
                1709096400
            ],
            [
                5.75,
                1709182800
            ],
            [
                5.59,
                1709269200
            ],
            [
                5.16,
                1709528400
            ],
            [
                5.04,
                1709614800
            ],
            [
                5.18,
                1709701200
            ],
            [
                5.28,
                1709787600
            ],
            [
                5.22,
                1709874000
            ],
            [
                5.14,
                1710129600
            ],
            [
                5.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5587,
        "drug_name": "BREXAFEMME (ibrexafungerp) - (CANDLE)",
        "clinical_trial_id": "NCT04029116",
        "has_trial_insight_page": 0,
        "indication": "Recurrent Vulvovaginal candidiasis (rVVC), Vaginal yeast infections",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-12-01",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/SCYX\/news\/102822",
        "note": "FDA Approved on December 1, 2022.",
        "company_entity_id": 275,
        "company_ticker": "SCYX",
        "company_name": "SCYNEXIS Inc.",
        "company_price": "1.6000",
        "company_change": -0.010000000000000009,
        "company_percent_change": -0.62,
        "company_optionable": 1,
        "company_number_of_shares": 37207799,
        "price_change_sparkline": [
            [
                2.06,
                1706677200
            ],
            [
                2.11,
                1706763600
            ],
            [
                2.14,
                1706850000
            ],
            [
                2.05,
                1707109200
            ],
            [
                1.995,
                1707195600
            ],
            [
                2,
                1707282000
            ],
            [
                1.92,
                1707368400
            ],
            [
                1.925,
                1707454800
            ],
            [
                1.81,
                1707714000
            ],
            [
                1.8,
                1707800400
            ],
            [
                1.82,
                1707886800
            ],
            [
                1.78,
                1707973200
            ],
            [
                1.72,
                1708059600
            ],
            [
                1.77,
                1708405200
            ],
            [
                1.7,
                1708491600
            ],
            [
                1.65,
                1708578000
            ],
            [
                1.68,
                1708664400
            ],
            [
                1.72,
                1708923600
            ],
            [
                1.7,
                1709010000
            ],
            [
                1.7,
                1709096400
            ],
            [
                1.62,
                1709182800
            ],
            [
                1.62,
                1709269200
            ],
            [
                1.63,
                1709528400
            ],
            [
                1.65,
                1709614800
            ],
            [
                1.67,
                1709701200
            ],
            [
                1.69,
                1709787600
            ],
            [
                1.66,
                1709874000
            ],
            [
                1.61,
                1710129600
            ],
            [
                1.6,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6748,
        "drug_name": "REZLIDHIA (olutasidenib)",
        "clinical_trial_id": "NCT02719574",
        "has_trial_insight_page": 1,
        "indication": "Acute myeloid leukemia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-12-01",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/RIGL\/news\/102927",
        "note": "Approved December 1, 2022.",
        "company_entity_id": 264,
        "company_ticker": "RIGL",
        "company_name": "Rigel Pharmaceuticals Inc.",
        "company_price": "1.4900",
        "company_change": -0.020000000000000018,
        "company_percent_change": -1.3199999999999998,
        "company_optionable": 1,
        "company_number_of_shares": 175377812,
        "price_change_sparkline": [
            [
                1.17,
                1706677200
            ],
            [
                1.2,
                1706763600
            ],
            [
                1.14,
                1706850000
            ],
            [
                1.17,
                1707109200
            ],
            [
                1.22,
                1707195600
            ],
            [
                1.12,
                1707282000
            ],
            [
                1.14,
                1707368400
            ],
            [
                1.2,
                1707454800
            ],
            [
                1.21,
                1707714000
            ],
            [
                1.12,
                1707800400
            ],
            [
                1.18,
                1707886800
            ],
            [
                1.22,
                1707973200
            ],
            [
                1.17,
                1708059600
            ],
            [
                1.14,
                1708405200
            ],
            [
                1.12,
                1708491600
            ],
            [
                1.3,
                1708578000
            ],
            [
                1.32,
                1708664400
            ],
            [
                1.42,
                1708923600
            ],
            [
                1.5,
                1709010000
            ],
            [
                1.55,
                1709096400
            ],
            [
                1.52,
                1709182800
            ],
            [
                1.55,
                1709269200
            ],
            [
                1.47,
                1709528400
            ],
            [
                1.48,
                1709614800
            ],
            [
                1.56,
                1709701200
            ],
            [
                1.53,
                1709787600
            ],
            [
                1.57,
                1709874000
            ],
            [
                1.51,
                1710129600
            ],
            [
                1.49,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6748,
        "drug_name": "REZLIDHIA (olutasidenib)",
        "clinical_trial_id": "NCT02719574",
        "has_trial_insight_page": 1,
        "indication": "Acute myeloid leukemia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-12-01",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/RIGL\/news\/102927",
        "note": "Approved December 1, 2022.",
        "company_entity_id": 385,
        "company_ticker": "NVO",
        "company_name": "Novo Nordisk A\/S",
        "company_price": "135.1100",
        "company_change": 3.87,
        "company_percent_change": 2.95,
        "company_optionable": 1,
        "company_number_of_shares": 4510000000,
        "price_change_sparkline": [
            [
                114.74,
                1706677200
            ],
            [
                115.79,
                1706763600
            ],
            [
                113.7,
                1706850000
            ],
            [
                118.26,
                1707109200
            ],
            [
                117.61,
                1707195600
            ],
            [
                118.66,
                1707282000
            ],
            [
                118.39,
                1707368400
            ],
            [
                121.2,
                1707454800
            ],
            [
                120.53,
                1707714000
            ],
            [
                119.99,
                1707800400
            ],
            [
                123.29,
                1707886800
            ],
            [
                121.75,
                1707973200
            ],
            [
                124.01,
                1708059600
            ],
            [
                121.45,
                1708405200
            ],
            [
                120.93,
                1708491600
            ],
            [
                124.52,
                1708578000
            ],
            [
                123.45,
                1708664400
            ],
            [
                123.49,
                1708923600
            ],
            [
                122.23,
                1709010000
            ],
            [
                121.54,
                1709096400
            ],
            [
                119.77,
                1709182800
            ],
            [
                124.23,
                1709269200
            ],
            [
                127.95,
                1709528400
            ],
            [
                124.65,
                1709614800
            ],
            [
                124.75,
                1709701200
            ],
            [
                135.92,
                1709787600
            ],
            [
                133.07,
                1709874000
            ],
            [
                131.24,
                1710129600
            ],
            [
                135.11,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9814,
        "drug_name": "Bivalent BNT162b2",
        "clinical_trial_id": "NCT05543616",
        "has_trial_insight_page": 0,
        "indication": "Omicron BA.4\/BA.5-adapted bivalent COVID-19 vaccine",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-12-08",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/PFE\/news\/104020",
        "note": "EUA granted for children under 5 December 8, 2022.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9814,
        "drug_name": "Bivalent BNT162b2",
        "clinical_trial_id": "NCT05543616",
        "has_trial_insight_page": 0,
        "indication": "Omicron BA.4\/BA.5-adapted bivalent COVID-19 vaccine",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-12-08",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/PFE\/news\/104020",
        "note": "EUA granted for children under 5 December 8, 2022.",
        "company_entity_id": 707,
        "company_ticker": "BNTX",
        "company_name": "BioNTech SE",
        "company_price": "95.7300",
        "company_change": -0.5700000000000001,
        "company_percent_change": -0.5900000000000001,
        "company_optionable": 1,
        "company_number_of_shares": 240993998,
        "price_change_sparkline": [
            [
                95.04,
                1706677200
            ],
            [
                94.51,
                1706763600
            ],
            [
                92.65,
                1706850000
            ],
            [
                93.35,
                1707109200
            ],
            [
                96,
                1707195600
            ],
            [
                95.05,
                1707282000
            ],
            [
                94.1,
                1707368400
            ],
            [
                93.14,
                1707454800
            ],
            [
                93.86,
                1707714000
            ],
            [
                90.58,
                1707800400
            ],
            [
                91.46,
                1707886800
            ],
            [
                92.91,
                1707973200
            ],
            [
                91.67,
                1708059600
            ],
            [
                91.24,
                1708405200
            ],
            [
                92.74,
                1708491600
            ],
            [
                93.57,
                1708578000
            ],
            [
                93.97,
                1708664400
            ],
            [
                93.52,
                1708923600
            ],
            [
                92.79,
                1709010000
            ],
            [
                91.43,
                1709096400
            ],
            [
                88.96,
                1709182800
            ],
            [
                90.94,
                1709269200
            ],
            [
                89.3,
                1709528400
            ],
            [
                90.52,
                1709614800
            ],
            [
                91.39,
                1709701200
            ],
            [
                91.09,
                1709787600
            ],
            [
                91.27,
                1709874000
            ],
            [
                96.3,
                1710129600
            ],
            [
                95.73,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7803,
        "drug_name": "KRAZATI (adagrasib)",
        "clinical_trial_id": "NCT03785249",
        "has_trial_insight_page": 0,
        "indication": "Non-small cell lung cancer (NSCLC) with a KRASG12C Mutation",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-12-13",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/MRTX\/news\/104703",
        "note": "Approved December 13, 2022.",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": [
            {
                "label": "Breakthrough Therapy Designation (BTD)",
                "abbreviation": "BTD",
                "description": "Breakthrough Therapy Designation (BTD)",
                "description_html": "<p>Breakthrough Therapy Designation (BTD)<\/p>\n"
            }
        ]
    },
    {
        "id": 7803,
        "drug_name": "KRAZATI (adagrasib)",
        "clinical_trial_id": "NCT03785249",
        "has_trial_insight_page": 0,
        "indication": "Non-small cell lung cancer (NSCLC) with a KRASG12C Mutation",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-12-13",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/MRTX\/news\/104703",
        "note": "Approved December 13, 2022.",
        "company_entity_id": 484,
        "company_ticker": "ZLAB",
        "company_name": "Zai Lab Limited",
        "company_price": "19.5400",
        "company_change": -0.47,
        "company_percent_change": -2.35,
        "company_optionable": 1,
        "company_number_of_shares": 99208743,
        "price_change_sparkline": [
            [
                21.57,
                1706677200
            ],
            [
                22.51,
                1706763600
            ],
            [
                22.5,
                1706850000
            ],
            [
                22.12,
                1707109200
            ],
            [
                21.61,
                1707195600
            ],
            [
                19.66,
                1707282000
            ],
            [
                19.605,
                1707368400
            ],
            [
                18.68,
                1707454800
            ],
            [
                18.21,
                1707714000
            ],
            [
                17.73,
                1707800400
            ],
            [
                19.39,
                1707886800
            ],
            [
                19.89,
                1707973200
            ],
            [
                20.64,
                1708059600
            ],
            [
                19.24,
                1708405200
            ],
            [
                19.91,
                1708491600
            ],
            [
                20.08,
                1708578000
            ],
            [
                19.94,
                1708664400
            ],
            [
                20.99,
                1708923600
            ],
            [
                22.49,
                1709010000
            ],
            [
                20.8,
                1709096400
            ],
            [
                20.98,
                1709182800
            ],
            [
                21.1,
                1709269200
            ],
            [
                20.42,
                1709528400
            ],
            [
                18.91,
                1709614800
            ],
            [
                19.8,
                1709701200
            ],
            [
                19.16,
                1709787600
            ],
            [
                18.91,
                1709874000
            ],
            [
                20.01,
                1710129600
            ],
            [
                19.54,
                1710216000
            ]
        ],
        "statuses": [
            {
                "label": "Breakthrough Therapy Designation (BTD)",
                "abbreviation": "BTD",
                "description": "Breakthrough Therapy Designation (BTD)",
                "description_html": "<p>Breakthrough Therapy Designation (BTD)<\/p>\n"
            }
        ]
    }
]